Guest Author: Christian Pereira, Agribusiness Strategist at Bizup Strategy, specializing in growth strategies and M&A.
13 August 2026, São Paulo: Earlier this year, Syngenta in Brazil declared: “We want to be number one in biologicals.”
My first reaction to statements like this is healthy skepticism. Not because I doubt the company, but because every major player in the industry is saying exactly the same thing.
Bayer is targeting €1.5 billion in biologicals by 2035, a more than sevenfold increase from a €200 million base in 2022. Corteva is aiming for US$1 billion by the end of the decade, after spending roughly US$1.6 billion acquiring Stoller and Symborg. FMC wants US$2 billion by 2033. BASF is building the narrative for its agricultural division’s IPO in Frankfurt in 2027. UPL has launched a dedicated platform in Brazil.
Add up the stated ambitions of these companies, and they occupy nearly the entire global market projected for 2030.
When everyone wants to be number one, someone is overestimating their share of the pie.
But there’s a piece of news from the past few weeks that, in my reading, explains Syngenta’s urgency better than any corporate target. And it has nothing to do with agronomy.
The IPO Shifts the Reading a Bit
Two weeks ago came the news: Syngenta’s IPO has been delayed again, with 2027 now the base-case scenario. The listing would be in Hong Kong, sized at roughly US$5 billion, though earlier rounds of market discussion floated figures as high as US$10 billion.
The reasons cited were geopolitical instability, the impact of the Strait of Hormuz closure on energy and fertilizer costs, and longer regulatory approval timelines tied to the company’s exposure to the seed business.
It’s worth recalling the full history: Syngenta first tried to go public in Shanghai back in 2021, initially on the STAR Market, then shifted to the main board in 2023, and ultimately withdrew the application in March 2024. From there, the focus moved to Hong Kong. That’s more than five years of trying to open up capital.
Now connect the dots.
A company that needs to sell a growth story to Asian investors — while its chemical business faces price compression and has declined in Latin America — finds in biologicals exactly what an investment thesis needs: double-digit growth, a sustainability narrative, and an expanding addressable market.
Biologicals aren’t just an agronomic bet for Syngenta. They’re the growth chapter of a multi-billion-dollar IPO prospectus.
This cuts both ways, and it’s worth being honest about both.
On one hand, it signals real capital commitment. A narrative that goes to market needs to be backed by auditable facts: plants, registrations, launches, revenue.
On the other, it means reading the targets through the filter of pre-IPO messaging, which tends toward optimism.
And there’s a leadership transition few outside Brazil have connected to this story: on August 1, Hengde Qin takes over as global CEO, succeeding Jeff Rowe, who is moving to ADM as COO. Qin isn’t an outsider — he’s an internal executive. He served as COO and Head of Seeds, and before that as CFO and CHRO of Syngenta Group, and earlier led the China operation. He brings a mix of operational, financial and commercial experience, with real credibility to engage Asian capital markets.
The Most Strategic Detail in the Latest Launch
Last week Syngenta launched a mycorrhizal fungi-based biological in Brazil, aimed at improving nutrient and water absorption efficiency, with the company’s own trials showing yield gains equivalent to more than five bags of soybeans per hectare.
What caught my attention wasn’t the technology. It was the business model.
The product was developed in partnership with GroundWork BioAg, an Israeli company that manufactures and supplies for Latin America and Europe. Syngenta commercializes it under its own brand.
The technology belongs to a third party. What Syngenta brings is brand, regulatory registration, channel, and sales force.
And this pattern of alliances repeats: a partnership with Biotrop, a collaboration with Provivi, the acquisition of Novartis’s library of natural compounds to work with metabolites, RNAi and peptides.
The giants aren’t winning this race on the active ingredient. They’re winning on the channel — and buying the active ingredient from whoever knows how to make it.
That’s the clearest confirmation of where the real competitive moat sits. And, counterintuitively, it’s good news for biologicals companies without a multinational’s balance sheet.
If the Scarce Asset Is Channel, the Question Changes
Brazil’s biologicals market has hundreds of companies operating in it, and no single player holds a dominant position. It’s reasonable to project that the top five will grow from roughly a third of the market today to somewhere close to 60% by 2030 — a concentration pattern already seen in other fragmented agricultural markets once large players arrive with capital and execution discipline.
In other words: consolidation isn’t a hypothesis. It’s a trajectory with a date attached.
And if the scarce asset is distribution rather than technology, the strategic question for a pure-play biologicals company stops being “how do I compete with Syngenta?” and becomes “do I want to compete with it, or do I want to supply it?”
Three positioning strategies are viable, and they aren’t mutually exclusive:
Become a technology platform, not a product company. License to the majors instead of chasing the same farmer. Lower margin per unit, but far greater scale and predictability — without needing to build a sales force of hundreds of people. Symbiomics already did this with Stoller/Corteva.
Consolidate to become the desirable asset. In a fragmented market headed toward concentration, whoever builds a real-scale platform becomes a strategic target commanding a high multiple. Several mid-sized players are already moving in this direction; Biotrop proved the thesis when it was acquired by Biobest.
Dominate niches where integration isn’t an advantage. Specific crops, specific regions, agronomic problems where deep technical selling matters more than broad portfolio.
Which of these three paths is your company actually executing — not just considering?
Where I Still Hold On to Skepticism
If we assume the future is an integrated chemical-plus-biological offering — and Syngenta itself claims it will be one of the few companies able to “deliver both” — the structural advantage of the majors is real. Farmers operating on thin margins value simplicity, trust, and a single technical point of contact.
But there still isn’t enough evidence to pick the winners.
Biologicals represent somewhere between 2% and 7% of the majors’ crop protection sales. None of them collapses if the strategy fails. Pure players, on the other hand, have existential focus — and they keep growing faster than the market.
The history of other industries suggests a pattern: in fragmented markets with fast-evolving technology, large incumbents rarely win through innovation. They win by buying, licensing, or waiting for the market to mature before applying scale.
That’s how it played out in craft beer, in natural cosmetics, in healthy foods. Innovation was born outside the giants and migrated inward through acquisition.
Which means the game over the next five years isn’t about who has the best technology.
The Question That Remains
A market with hundreds of companies, no clear owner, and double-digit growth isn’t a mature market. It’s a market waiting for whoever has the strategic clarity to claim it.
Syngenta has channel, capital, and strong momentum in Brazil. The other majors have scale and ambitious targets. The pure players have focus and speed.
Nobody has won anything yet.
The question isn’t who will lead in 2030. It’s whether your company knows, with brutal honesty, which of these three games it’s playing — and whether it’s playing that game with enough discipline to still be standing when consolidation arrives.
Global Agriculture is an independent international media platform covering agri-business, policy, technology, and sustainability. For editorial collaborations, thought leadership, and strategic communications, write to pr@global-agriculture.com
